Skip to content

The efficacy and safety of pulsed dye laser in the treatment of rosacea

Study on the mechanism of pulsed dye laser in the treatment of rosacea

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038936
Enrollment
Unknown
Registered
2020-10-10
Start date
2020-10-12
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

Group A:pulsed dye laser treatment
Group B:intense pulsed light

Sponsors

Department of Dermatology, Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18 to 65 years with clinical diagnosis of rosacea; 2. Those who have not received any medication or photoelectric treatment for rosacea within 3 months, and have no plan to have any facial skin surgery or treatment within half a year; 3. The subjects have good compliance, can and are willing to follow the research guidance and the treatment restrictions specified in this protocol, and can complete all the study visits as required; 4. Read and sign the informed consent form before the study.

Exclusion criteria

Exclusion criteria: 1. There are other facial inflammatory diseases in the treatment site: solar dermatitis, facial eczema, facial contact dermatitis, facial recurrent dermatitis, lupus erythematosus, dermatomyositis, etc; 2. Fever (body temperature above 37.5 degrees C) or clinical active infection that significantly affects clinical trials; 3. Scar constitution; 4. Skin tumor was found in the treatment site; 5. Exposure history in recent month; 6. Have a history of injection of fillers in the past two weeks; 7. Grinding history in recent half a year; 8. Malignant tumor of systemic organs and blood system and malignant tumor; 9. Have a history of HIV infection or HIV antibody positive, or have a history of HSV attack in the treatment site in recent three months; 10. Low immune function and systemic failure; serious heart, liver, lung, kidney and other important organ diseases are not suitable to participate in clinical trials, such as renal insufficiency requiring dialysis or renal transplantation; 11. Poor glycemic control in diabetes mellitus (fasting blood glucose > 7.0mmol/l, postprandial 2-hour blood glucose > 11.1mmol/l, A1C > 6.5%); 12. Hematological diseases, including hematological neoplasms, abnormal coagulation function and severe hematopoietic dysfunction; 13. Drug, tobacco and alcohol addiction; 14. Have a clear history of mental illness; 15. Taking glucocorticoids or other immunosuppressants, anticoagulants, or suffering from autoimmune diseases; 16. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
clinician improvment assessment;patient global improvment;dermatologic quality of life;Transeipdermal water loss (TEWL);Erythema index;Melanin index;visual analog scale for painess;

Countries

China

Contacts

Public ContactShuxian Yan

Department of Dermatology, Huashan Hospital, Fudan University

shuxianyan0225@126.com+86 13817200326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026